New Interim CFO at BICO

Mikael Engblom will take the position as interim CFO for BICO (publ) from 29 April 2022 until a new permanent CFO is in place. Engblom will be part of Group management during this period.

BICO announced on April 26, 2022 that the former CFO has left the company and that a recruitment process for a new CFO has begun. While the process is ongoing, Mikael Engblom will assume the role of interim CFO at BICO. Engblom most recently came from the role of CFO at Vitrolife. Prior to that, he worked as a controller at Vitrolife and Volvo Cars. He has a master's degree in business administration from the University of Gothenburg.

“It is very exciting that Mikael will join us as interim CFO during this period. His previous experience as CFO at Vitrolife speaks for itself. He played a key role in transforming the company from a small niche company to a very profitable market-leading player on Large Cap. Mikael will create value for BICO at a stage where we focus on our profitability and are building a financially sustainable organization and continue to build a strong finance department. At the same time, the recruitment of an internationally experienced CFO continues who can assist the company in achieving the goals that the market and shareholders expect and that the company has previously communicated.” Erik Gatenholm, CEO of BICO, comments.

For further information, please contact:

Åsa Hillsten, Head of IR, BICO

Phone (EU): +46 70-081 81 17

Email: ash@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on April, 29, 2022 at 16:00 (CEST).

About BICO

Founded in 2016, BICO (formerly CELLINK) is enabling the future of life-saving treatments by reducing the organ shortage and accelerating drug development by providing accessible life science solutions that combine biology and technology (bioconvergence). The company focuses on developing, manufacturing, selling, and supporting its life sciences equipment, consumables, and reagents for both manufacturing as well as research purposes. BICO has more than 25,000 products in the field, sales in more than 65 countries, delivers to all top 20 pharmaceutical companies, and have been cited in more than 10,000 scientific publications. BICO is listed on Nasdaq Stockholm under: BICO.